Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High vs Low Concentration Iodine for Esophageal Chromoendoscopy
NCT06063941Completed
- Sponsor
- Xijing Hospital of Digestive Diseases
- Start
- Oct 2023
- Primary completion
- Apr 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of Lugol's solution in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Xijing Hospital of Digestive Diseases. Primary endpoint: Visual Analogue Scale scores at 30 months. Started Oct 2023; status: completed.
02
Drugs
Lugol's solution
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06063941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06063941.